Brief: Clarity Commences Combat Theranostic Prostate Cancer Trial In The US
20/06/2023 14:19
June 20 (Reuters) - Clarity Pharmaceuticals Ltd
CU6.AX :
* CLARITY COMMENCES COMBAT THERANOSTIC PROSTATE CANCER TRIAL
IN
THE US
Source text for Eikon: ID:nPn3VCP4Ca
Further company coverage: CU6.AX
(Reuters.Briefs@thomsonreuters.com)
Recent news on Clarity Pharmaceuticals
See all newsBrief: Clarity Pharmaceuticals Signs Commercial Manufacturing Agreement
Brief: Clarity Signs A Large-Scale Manufacturing Supply Agreement For Copper-64 With Theragenics
Brief: Clarity Pharmaceuticals Signs A Large-Scale Manufacturing Supply Agreement
Australia's Clarity Pharmaceuticals rises on bagging cancer detection agent supply
Australia's Clarity Pharma surges as US FDA approves trial